Ginkgo Bioworks Makes Major Pivot
Ginkgo Bioworks reported Q4 revenues of $33 million, down 24% year-over-year, and missing estimates by over $4 million. Cell Engineering, expected to drive growth, delivered just $125 million in 2025 ...
Fiscal Year: January - December
Ginkgo Bioworks Holdings, Inc. (DNA), listed on the NYSE, has a market capitalization of $382.42M. As of Mar 19, 2026, the stock is trading at $6.49 per share@else an unavailable price , offering investors a clear view of its current market value. Ginkgo Bioworks Holdings, Inc. is a prominent player in the industry sector, attracting both institutional and retail investors due to its performance and potential.
With a P/E ratio of N/A , investors can assess the stock's valuation in comparison to its earnings. A P/E ratio is a crucial indicator for value investors, showing whether the stock is over or undervalued relative to its current earnings. Ginkgo Bioworks Holdings, Inc. also offers a dividend yield of N/A , making it an attractive option for income-focused investors who seek regular dividends.
Our Discounted Cash Flow (DCF) analysis reveals that Ginkgo Bioworks Holdings, Inc. (DNA) may be overvalued compared to its intrinsic worth. However, to see the exact DCF fair value, please Login or Upgrade for access.
The proprietary SS Score for Ginkgo Bioworks Holdings, Inc. is a unique metric that analyzes the company's financial health and growth potential. The score takes into account critical factors such as revenue growth, net income, free cash flow (FCF) compound annual growth rate (CAGR), the trend of shares outstanding, and the debt-to-FCF ratio. This helps investors to make a more informed decision, as an undervalued stock might still have poor financial fundamentals.
To view the detailed SS Score for Ginkgo Bioworks Holdings, Inc., Login or Upgrade for access.
The Price to Free Cash Flow (P/FCF) ratio for Ginkgo Bioworks Holdings, Inc. is N/A , offering insights into how much investors are paying for the company's free cash flow. A lower P/FCF ratio typically suggests that the stock is undervalued, while a higher ratio may indicate overvaluation.
In summary, Ginkgo Bioworks Holdings, Inc. (DNA) has shown consistent financial performance, as illustrated by the financial charts above, which track its revenue growth, net income, free cash flow, and shares outstanding over the past several years. These metrics provide investors with key insights into the company's past and projected future performance. Investors should use the SS Score alongside the DCF Fair Value to make better-informed decisions about whether to buy or hold the stock.
*This analysis is for informational purposes only and does not constitute investment advice. Always read the company's 10-K filings and do your own research before making any investment decisions.
Whether Ginkgo Bioworks Holdings, Inc. (DNA) is a good stock to buy depends on various factors, including its financial health, market conditions, and your investment strategy. Our analysis indicates that the stock may be overvalued compared to its intrinsic value. However, it is important to assess the SS Score and review the company's fundamentals before making any investment decisions.
The fair value of Ginkgo Bioworks Holdings, Inc. (DNA) is determined through our Discounted Cash Flow (DCF) analysis. This value represents the intrinsic worth of the stock based on its expected future cash flows. To view the specific fair value, consider subscribing to our service for complete access.
The SS Score is a proprietary financial quality metric that assesses factors such as revenue growth, net income, free cash flow growth, and debt levels. It helps investors evaluate the overall financial health of Ginkgo Bioworks Holdings, Inc.. To access the full SS Score, consider upgrading your subscription.
Ginkgo Bioworks Holdings, Inc. is a significant player in the industry sector, with a market capitalization of $382.42M and a competitive P/E ratio of N/A . Investors should compare these metrics with industry peers to gauge whether Ginkgo Bioworks Holdings, Inc. is outperforming or underperforming within its sector.
Ginkgo Bioworks reported Q4 revenues of $33 million, down 24% year-over-year, and missing estimates by over $4 million. Cell Engineering, expected to drive growth, delivered just $125 million in 2025 ...
BOSTON, March 2, 2026 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA) today announced the official launch of Ginkgo Cloud Lab. This new interface allows researchers to transition their benchwork to Ginkgo...
Ginkgo Bioworks Holdings, Inc. (DNA) Q4 2025 Earnings Call Transcript
Ginkgo Bioworks (NYSE: DNA) shares are down following the company's fourth-quarter and full-year 2025 financial report.
Ginkgo provides an update on its fourth quarter financial results BOSTON, Feb. 26, 2026 /PRNewswire/ -- Ginkgo Bioworks Holdings, Inc. (NYSE: DNA, "Ginkgo") today announced its results for the fourth ...
Presentation and Q&A session scheduled for post-market on Thursday, February 26, 2026 BOSTON, Feb. 19, 2026 /PRNewswire/ -- Ginkgo Bioworks Holdings, Inc. (NYSE: DNA, "Ginkgo") today announced that it...
Collaboration aims to develop a commercialization-ready microorganism to manufacture next-generation peptide crop solutions at grower-friendly costs BOSTON, Feb. 18, 2026 /PRNewswire/ -- Ginkgo Biowor...
Research conducted in collaboration with OpenAI using Ginkgo's cloud laboratory Preprint describes how GPT-5-driven autonomous lab significantly reduced reaction costs in cell-free protein synthesis G...
BOSTON, Jan. 13, 2026 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA) announced today that Co-Founder and CEO Jason Kelly is scheduled to present at the 44th Annual J.P. Morgan Healthcare Conference on Th...
BOSTON , Dec. 22, 2025 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA) today announced its partnership with Carnegie-Mellon University (CMU) for an award by the Advanced Research Projects Agency for Healt...
Collaboration reduces time in fermenting complex bacterial strains, enabling continued focus on next-gen biological crop solutions. BOSTON and PLANO, Texas , Dec. 17, 2025 /PRNewswire/ -- Ginkgo Biowo...
ProteoNic licenses its 2G UNic technology to Ginkgo Bioworks for a BARDA-backed consortium to boost fast, cost‑effective mAb production against filoviruses
BOSTON , Dec. 9, 2025 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA) today announced its partnership with Deep Origin on a 4.5-year project funded by the Advanced Research Projects Agency for Health (ARP...
BOSTON , Dec. 5, 2025 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA) today announced it has been awarded by the Environmental Molecular Sciences Laboratory (EMSL) at Pacific Northwest National Laboratory...
CAMBRIDGE, Mass. , Dec. 3, 2025 /PRNewswire/ -- STRM.BIO, a start-up biotechnology company pioneering non-viral delivery technologies for in vivo cell and gene therapy, today announced that it has bee...
BOSTON , Nov. 18, 2025 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA) today announced its partnership with the Institute for Genomic Biology at the University of Illinois Urbana-Champaign on a five-year ...
Ginkgo Bioworks shares dropped on Friday as revenue growth continues to disappoint and cash burn persists despite improvements. Q3 results missed expectations, with adjusted revenues tumbling and oper...
Ginkgo Bioworks Holdings, Inc. ( DNA) Q3 2025 Earnings Call November 6, 2025 4:30 PM EST Company Participants Daniel Waid Marshall Jason Kelly - Founder, CEO & Director Steven Coen - Chief Accounting...
Ginkgo provides an update on its third quarter financial results BOSTON , Nov. 6, 2025 /PRNewswire/ -- Ginkgo Bioworks Holdings, Inc. (NYSE: DNA, "Ginkgo") today announced its results for the third qu...
Ginkgo and Partners to Develop Monoclonal Antibody Biomanufacturing Innovations and to Produce an Anti-Filovirus Medical Countermeasure BOSTON , Nov. 3, 2025 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA...
BOSTON , Oct. 31, 2025 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA) today announced that the company has extended its multi-year strategic partnership with Bayer to advance research and development of ...
Presentation and Q&A session scheduled for post-market on Thursday, November 6, 2025 BOSTON , Oct. 30, 2025 /PRNewswire/ -- Ginkgo Bioworks Holdings, Inc. (NYSE: DNA, "Ginkgo") today announced that it...
Ginkgo Bioworks to apply its RNA construct design expertise to develop long-lived, tissue-specific, and highly potent in vivo CAR therapies for autoimmune diseases BOSTON , Oct. 23, 2025 /PRNewswire/ ...
BOSTON--(BUSINESS WIRE)--Ginkgo Bioworks announced a series of new initiatives to accelerate the application of artificial intelligence in biologics drug discovery.
BOSTON , Aug. 29, 2025 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA) today released the following notice: UNITED STATES DISTRICT COURT NORTHERN DISTRICT OF CALIFORNIA OAKLAND DIVISION WEINING HU, deriva...
Below estimates were sourced from SimplyWallSt and are intended for educational purposes only as a baseline for the analysis.
| Year | FCF Estimate | % | # Analysts |
|---|---|---|---|
| 2025 | -308.36M | -19.30% | Est @-19.3% |
| 2026 | -234.60M | -23.92% | Est @-23.9% |
| 2027 | -259.11M | 10.45% | Est @10.4% |
| 2028 | -280.17M | 8.13% | Est @8.1% |
| 2029 | -298.41M | 6.51% | Est @6.5% |
| 2030 | -313.45M | 5.04% | Est @5.0% |
| 2031 | -326.92M | 4.30% | Est @4.3% |
| 2032 | -339.26M | 3.77% | Est @3.8% |
| 2033 | -350.83M | 3.41% | Est @3.4% |
| 2034 | -361.15M | 2.94% | Est @2.9% |
Below are the FCF estimates with the discount factor and the calculated present value with the terminal value that led the results above.
| Year | FCF | Discount Factor | PV of Future FCF |
|---|---|---|---|
| 2023A | -336.30M | 1.00 | -336.30M |
| 2024A | -382.13M | 1.00 | -382.13M |
| 2025E | -308.36M | 1.08 | -284.42M |
| 2026E | -234.60M | 1.18 | -199.58M |
| 2027E | -259.11M | 1.27 | -203.32M |
| 2028E | -280.17M | 1.38 | -202.78M |
| 2029E | -298.41M | 1.50 | -199.21M |
| 2030E | -313.45M | 1.62 | -193.01M |
| 2031E | -326.92M | 1.76 | -185.67M |
| 2032E | -339.26M | 1.91 | -177.72M |
| 2033E | -350.83M | 2.07 | -169.51M |
| 2034E | -361.15M | 2.24 | -160.95M |
| Terminal | -6.26B | 2.24 | -2.79B |
The information given by Studying Stocks and provided in the web and/or mobile applications (Platforms) is only factual information and should not be considered financial advice.
Any information contained in this website has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.
When creating an account, you acknowledge that you are:
We retain the right to cancel your account for any reason, or refuse your account creation request.
The information on our Platforms is not comprehensive and is intended to provide a summary of the subject matter covered. While we use all reasonable attempts to ensure the accuracy and completeness of the data and information on our Platforms, to the extent permitted by law, we make no warranty regarding the information on these Platforms. You should monitor any changes to the information contained on these Platforms.
Furthermore we make no commitments in regards to the minimum amount of uptime that our platforms will maintain, although we will make ever reasonable attempt to ensure that the platforms are operational. Therefore, any reference of "latest", "current" and related words about the financial data presented here may not be up to date with the financial markets or represent reality of the information.
We are not liable to you or anyone else if interference with or damage to your computer systems occurs in connection with the use of these Platforms or a linked website. You must take your own precautions to ensure that whatever you select for your use from our Platforms is free of viruses or anything else (such as worms or Trojan horses) that may interfere with or damage the operations of your computer systems.
We may, from time to time and without notice, change or add to the Platforms (including the Terms) or the information, products or services described in it. However, we do not undertake to keep the Platforms updated. We are not liable to you or anyone else if errors occur in the information or the Platforms is not up-to-date.
Our Platforms may contain links to websites operated by third parties. Those links are provided for convenience and may not remain current or be maintained. Unless expressly stated otherwise, we do not endorse and are not responsible for the content on those linked websites and have no control over or rights in those linked websites.
These Platforms are for your personal, non-commercial use only. You may not modify, copy, distribute, transmit, display, perform, reproduce, publish, license, commercially exploit, create derivative works from, transfer, or sell any Content, software, products or services contained within these Platforms. You may not use these Platforms, or any of its Content, to further any commercial purpose, including any advertising or advertising revenue generation activity on your own website.
You must not do any act that we would deem to be inappropriate, is unlawful or is prohibited by any laws applicable to these Platforms, including but not limited to:
If we allow you to post any information to our Platforms, we have the right to take down this information at our sole discretion and without notice.
To the maximum extent permitted by law, we make no warranties or representations about these Platforms or the Content, including but not limited to warranties or representations that they will be complete, accurate or up-to-date, that access will be uninterrupted or error-free or free from viruses, or that these Platforms will be secure.
We reserve the right to restrict, suspend or terminate without notice your access to these Platforms, any Content, or any feature of these Platforms at any time without notice and we will not be responsible for any loss, cost, damage or liability that may arise as a result.
To the maximum extent permitted by law, in no event shall we be liable for any direct and indirect loss, damage or expense – irrespective of the manner in which it occurs – which may be suffered due to your use of our Platforms and/or the information or materials contained on it, or as a result of the inaccessibility of these Platforms and/or the fact that certain information or materials contained on it are incorrect, incomplete or not up-to-date.
This website utilises cookies. If you do not have cookies enabled in your web browser some functions of the site may not work as intended.